In addition, the JAK2 disease mutation R683G has a pathogenic counterpart in JAK1 and several mutations at the homologous JAK1 R724 site (namely to His, Gln, or Ser) have been detected in T- and B-ALL cohorts [62]. This evidence concerns the gene JAK2 and acute lymphoblastic leukemia.